Literature DB >> 21321148

Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.

Celine Vidaillac1, Molly E Steed, Michael J Rybak.   

Abstract

De-escalation and escalation therapeutic strategies are commonly employed by clinicians on the basis of susceptibility results and patient response. Since no in vitro or in vivo data are currently available to support one strategy over the other for daptomycin, we attempted to evaluate the effects of dose escalation and de-escalation on daptomycin activity against methicillin-resistant Staphylococcus aureus (MRSA) isolates using an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations. Three clinical MRSA isolates, including one heterogeneous vancomycin-intermediate S. aureus (hVISA) isolate and one vancomycin-intermediate S. aureus (VISA) isolate, were exposed to daptomycin at 10 or 6 mg/kg of body weight/day for 8 days using a starting inoculum of ∼10(9) CFU/g of vegetations, with dose escalation and de-escalation initiated on the fourth day. Daptomycin MIC values ranged from 0.5 to 1 μg/ml. In the PK/PD model, high-dose daptomycin (10 mg/kg/day) and de-escalation simulation (10 to 6 mg/kg/day) appeared to be the most efficient regimens against the three tested isolates, exhibiting the fastest bactericidal activity (4 to 8 h) compared to that of the standard regimen of 6 mg/kg/day and the escalation therapy of 6 to 10 mg/kg/day. The differences in the numbers of CFU/g observed between dose escalation and de-escalation were significant for the hVISA strain, with the de-escalation simulation exhibiting a better killing effect than the escalation simulation (P<0.024). Although our results need to be carefully considered, the use of high-dose daptomycin up front demonstrated the most efficient activity against the tested isolates. Different therapeutic scenarios including isolates with higher MICs and prolonged drug exposures are warranted to better understand the outcomes of escalation and de-escalation strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321148      PMCID: PMC3088203          DOI: 10.1128/AAC.01291-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Gradient plate method to induce Streptococcus pyogenes resistance.

Authors:  H Carsenti-Etesse; P M Roger; B Dunais; S Durgeat; G Mancini; M Bensoussan; P Dellamonica
Journal:  J Antimicrob Chemother       Date:  1999-10       Impact factor: 5.790

2.  Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary.

Authors:  D Landman; M Chockalingam; J M Quale
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

3.  Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci.

Authors:  J Quale; D Landman; G Saurina; E Atwood; V DiTore; K Patel
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

4.  Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Daptomycin dose-effect relationship against resistant gram-positive organisms.

Authors:  Raymond Cha; Richard G Grucz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

7.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 8.  Daptomycin.

Authors:  Kerry L Tedesco; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2004-01       Impact factor: 4.705

Review 9.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

10.  Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Authors:  Feng-Yee Chang; James E Peacock; Daniel M Musher; Patricia Triplett; Brent B MacDonald; Joseph M Mylotte; Alice O'Donnell; Marilyn M Wagener; Victor L Yu
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

View more
  4 in total

1.  Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly E Steed; Céline Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

2.  Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.

Authors:  Armando Gonzalez-Ruiz; Panayiotis Gargalianos-Kakolyris; Artur Timerman; Jayanta Sarma; Víctor José González Ramallo; Kamel Bouylout; Uwe Trostmann; Rashidkhan Pathan; Kamal Hamed
Journal:  Adv Ther       Date:  2015-06-25       Impact factor: 3.845

3.  Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy.

Authors:  Xiaoying Xu; Dmytro Khadzhynov; Harm Peters; Ricardo L Chaves; Kamal Hamed; Micha Levi; Natascia Corti
Journal:  Br J Clin Pharmacol       Date:  2016-10-28       Impact factor: 4.335

Review 4.  Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome.

Authors:  Christian Johann Lerche; Franziska Schwartz; Marie Theut; Emil Loldrup Fosbøl; Kasper Iversen; Henning Bundgaard; Niels Høiby; Claus Moser
Journal:  Front Cell Dev Biol       Date:  2021-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.